Vimarsana
Biggest News Aggregation in the World

Page 3 - Bio Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bio Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bio Ventures Today - Breaking & Trending Today

Nano-X Imaging Ltd. (NNOX) Q2 2022 Earnings Call Transcript - Vimarsana News

Nano-X Imaging Ltd. (NNOX) Q2 2022 Earnings Call Transcript

NNOX earnings call for the period ending June 30, 2022.

Source: fool.com
V-Bio Ventures Closes Second Fund, at EUR 110M - Vimarsana News

V-Bio Ventures Closes Second Fund, at EUR 110M

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

V-Bio Ventures raises EUR 110 million for its second fund and expands team - Vimarsana News

V-Bio Ventures raises EUR 110 million for its second fund and expands team

V-Bio Ventures raises EUR 110 million for its second fund and expands teamGhent, Belgium, 31 March 2022 – V-Bio Ventures announced the final closing of its second fund, V-Bio Fund 2, having raised EUR 110 million euro and exceeding its target of EUR 100 million.Together with their first fund, V-Bio Fund 1, V-B...

DeciBio Consulting Announces Debut Venture Fund, DeciBio Ventures, to Support Ground-Breaking Precision Medicine Companies - Vimarsana News

DeciBio Consulting Announces Debut Venture Fund, DeciBio Ventures, to Support Ground-Breaking Precision Medicine Companies

/PRNewswire/ -- DeciBio Consulting, LLC, a precision medicine-focused strategy consulting and market intelligence firm, has launched DeciBio Ventures. This...

Abalos Therapeutics Completes Series A Extension Bringing Total Raised to EUR 43 Million - Vimarsana News

Abalos Therapeutics Completes Series A Extension Bringing Total Raised to EUR 43 Million

Additional EUR 32.5 million will support clinical readiness and accelerate lead immuno-virotherapy candidates toward clinical proof-of-concept Abalos Therapeutics announced today an extension